Viva Biotech Holdings announced based on the preliminary assessment of the latest unaudited management accounts of the Group and information currently available, for the year ended December 31, 2020 (the "Year") the Group is expected to record a significant amount of net loss during the Year as compared to the net profit reported for the year ended December 31, 2019. Based on the information currently available, the Board considers that the significant net loss is mainly attributable to an extraordinary loss of approximately RMB600 million in relation to the Convertible Bonds issued in compliance with the International Financial Reporting Standards ("IFRS").